ATYR
NASDAQaTyr Pharma Inc.
Price$0.48-0.01 (-1.34%)
04:15 PM07:45 PM
News · 26 weeks33-33%
2026-02-012026-07-26
Mix2090d
- Other7(35%)
- Insider7(35%)
- SEC Filings5(25%)
- Earnings1(5%)
Latest news
25 items- PRaTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo. Company submitted protocol to FDA in June 2026 for planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will present a subgroup analysis of the Phase 3 EFZO-F
- SECAmendment: SEC Form SCHEDULE 13G/A filed by aTyr Pharma Inc.SCHEDULE 13G/A - aTYR PHARMA INC (0001339970) (Subject)
- PRLife Sciences Virtual Investor Forum Presentations Now Available for On-Demand ViewingNEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing. REGISTER AND VIEW PRESENTATIONS HERE Select companies are accepting 1x1 management meeting requests through June 19th. Please Schedule 1x1 Meetings here. The presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Presenting Companies CompanyTicker(s)MetaVia Inc.(NASDAQ:MTVA)Nasus Pharma Ltd.(NYSE:NSRX)CytoSorbents Corporation(NASD
- PRLife Sciences Virtual Investor Forum Agenda Announced for June 24th & 25thNEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings
- SECaTyr Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - aTYR PHARMA INC (0001339970) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by aTyr Pharma Inc.SCHEDULE 13G/A - aTYR PHARMA INC (0001339970) (Subject)
- SECaTyr Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - aTYR PHARMA INC (0001339970) (Filer)
- INSIDERDirector Schimmel Paul bought $49,630 worth of shares (100,000 units at $0.50) (SEC Form 4)4 - aTYR PHARMA INC (0001339970) (Issuer)
- SECSEC Form 10-Q filed by aTyr Pharma Inc.10-Q - aTYR PHARMA INC (0001339970) (Filer)
- SECaTyr Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - aTYR PHARMA INC (0001339970) (Filer)
- PRaTyr Pharma Announces First Quarter 2026 Results and Provides Corporate UpdateCompany to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint and KSQ-Lung as key secondary endpoint. On track to complete enrollment in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD in the first half of 2026. Ended the first quarter 2026 with $68.3 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical
- INSIDERSEC Form 4 filed by Director Coughlin Timothy4 - aTYR PHARMA INC (0001339970) (Issuer)
- INSIDERSEC Form 4 filed by Director Benevich Eric4 - aTYR PHARMA INC (0001339970) (Issuer)
- INSIDERSEC Form 4 filed by Director Gross Jane A4 - aTYR PHARMA INC (0001339970) (Issuer)
- INSIDERSEC Form 4 filed by Director Lucas Svetlana4 - aTYR PHARMA INC (0001339970) (Issuer)
- INSIDERSEC Form 4 filed by Director Zaknoen Sara4 - aTYR PHARMA INC (0001339970) (Issuer)
- INSIDERSEC Form 4 filed by Director Schimmel Paul4 - aTYR PHARMA INC (0001339970) (Issuer)
- PRaTyr Pharma to Participate in Upcoming Investor ConferencesSAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in May and June 2026. Details of the conferences appear below: Conference: RBC Capital Markets Global Healthcare ConferenceDate: Wednesday, May 20, 2026Location: New York, NYFormat: 1x1 Investor Meetings Conference: Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026Time: 3:45pm ETLocation: New York, NYFormat: Fireside ChatSpeaker: San
- SECaTyr Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - aTYR PHARMA INC (0001339970) (Filer)
- PRaTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C MeetingCompany to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for new Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint and KSQ-Lung as key secondary endpoint.Management to host conference call and webcast today at 4:30pm ET / 1:30pm PT. SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced th
- SECSEC Form DEFA14A filed by aTyr Pharma Inc.DEFA14A - aTYR PHARMA INC (0001339970) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by aTyr Pharma Inc.SCHEDULE 13G/A - aTYR PHARMA INC (0001339970) (Subject)
- SECSEC Form DEF 14A filed by aTyr Pharma Inc.DEF 14A - aTYR PHARMA INC (0001339970) (Filer)
- SECSEC Form PRE 14A filed by aTyr Pharma Inc.PRE 14A - aTYR PHARMA INC (0001339970) (Filer)
- SECSEC Form 10-K filed by aTyr Pharma Inc.10-K - aTYR PHARMA INC (0001339970) (Filer)
ATYR FAQ
6 questionsWhere does ATYR stock trade?
aTyr Pharma Inc. (ATYR) is listed on NASDAQ.What sector and industry is ATYR in?
aTyr Pharma Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did aTyr Pharma Inc. go public?
aTyr Pharma Inc. (ATYR) completed its IPO in 2015.What are analysts saying about ATYR?
aTyr Pharma Inc. has had 8 recent analyst actions on file. The most recent action was from RBC Capital Mkts: Sector Perform with a $150.00 price target on 2025-09-16.What companies are similar to ATYR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ATYR side-by-side with any of them on Quantisnow.How can I track ATYR on Quantisnow?
Quantisnow aggregates aTyr Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ATYR to receive live email and push alerts on every new disclosure.